Market Place
Sourcing Support
All News #Library
Biotech
Metsera sale architect swings to Structure
17 Apr 2026 //
FIERCE BIOTECH
Amylin`s Oral Obesity Assets Gain Momentum In 2026
06 Feb 2026 //
BIOSPACE
Pfizer Links Monthly GLP-1 To Competitive Weight Loss In Phase 2
04 Feb 2026 //
FIERCE BIOTECH
Pfizer Expedites Obesity Programs Amid Patent Cliff Challenge
13 Jan 2026 //
BIOSPACE
Pfizer wins $10 billion bidding war for Metsera as Novo Exist
08 Nov 2025 //
REUTERS
Pfizer`s New Prize Metsera Touts 14% Weight Loss For Glp-1
30 Sep 2025 //
FIERCE BIOTECH
Metsera`s MET-097i Shows Positive Phase 2b Results
29 Sep 2025 //
GLOBENEWSWIRE
Pfizer to Acquire Metsera and its Next-Gen Obesity Portfolio
24 Sep 2025 //
PRESS RELEASE
Metsera Showcases Next-Gen Obesity Portfolio at 61st EASD Meeting
11 Sep 2025 //
GLOBENEWSWIRE
Metsera Shares Early Data on Anti-Obesity Amylin Candidate
09 Jun 2025 //
ENDPTS
Metsera Closes IPO & Full Exercise of Underwriters’ Option
05 Feb 2025 //
GLOBENEWSWIRE
Obesity biotech Metsera files for a swift IPO
11 Jan 2025 //
FIERCE BIOTECH
Metsera Raises Another $215M for Long-Acting GLP-1
14 Nov 2024 //
BIOSPACE
Metsera Raises $215M for Long-Acting GLP-1 Obesity Treatment
13 Nov 2024 //
BIOSPACE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.